RxDoctor Payments DataLook up a doctor →

Sola Kim, MD

Pulmonary Disease · N Charleston, SCNPI 1508864968

Payments from drug & device makers

$15,106in general payments, 2019–2025

Across 501 payments — averaging $30.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • AstraZeneca$2K
  • GSK$1K
  • Veran Medical Technologies, Inc.$1K
  • Medical Device Business Services, Inc.$1K
  • Sanofi$856
  • plus $7K from 38 others

What the payments were for

  • Travel & lodging$3,20821%
  • Food & beverage$11,59077%
  • Education$3082%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,106 in reported general payments places this provider in the 75th percentile of 192 pulmonary disease providers in South Carolina.

See all pulmonary disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$169,789
Medicare patients
511
Services billed
1,780

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter427$354,898
NucalaMepolizumab72$280,404
OfevNintedanib Esylate23$276,843
Dupixent PenDupilumab44$171,459
Breo ElliptaFluticasone/Vilanterol118$59,759
Breztri AerosphereBudesonide/Glycopyr/Formoterol63$55,936
XolairOmalizumab13$48,446
Spiriva RespimatTiotropium Bromide27$23,650
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr30$21,646
SymbicortBudesonide/Formoterol Fumarate46$17,110
Wixela InhubFluticasone Propion/Salmeterol78$9,692
Fluticasone-SalmeterolFluticasone Propion/Salmeterol60$9,336
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate36$7,175
Albuterol Sulfate HfaAlbuterol Sulfate258$6,881
DuleraMometasone/Formoterol20$6,066

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta$1,326$716,707647 claims
Boehringer IngelheimOfev, Spiriva Respimat$841$300,49450 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,528$73,046109 claims
MerckDulera$108$6,06620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 192 pulmonary disease providers in South Carolina.

Other pulmonary disease in N Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →